Guidance Holds Amidst Losses
Health In Tech Reaffirms FY2026 Sales Target Despite Wider Quarterly Loss
Key Points
On August 13, 2026, Health In Tech, Inc. prepared an investor presentation that officers and other representatives intend to present at conferences and meetings.
The investor presentation is furnished as Exhibit 99.1 with the Form 8-K, making the material publicly accessible through the filing.
The 8-K includes forward-looking statements that are subject to safe harbor protections under the Private Securities Litigation Reform Act of 1995.
The information in Item 7.01 and Exhibit 99.1 is furnished rather than filed and is not intended to be incorporated by reference into other filings, which affects liabilities and disclosure scope.
Health In Tech (NASDAQ: HIT) reaffirmed its full-year 2026 revenue guidance of $45 million to $50 million, even as the company posted a wider-than-expected loss in Q2. The analyst consensus of $46.8 million sits comfortably inside that guided range, according to Benzinga.
Second-quarter revenue came in at $8.057 million, beating the $7.547 million estimate. But the earnings-per-share loss widened to $(0.04), missing the expected $(0.03) by 100%, according to ScanX Trade. Revenue also fell 13.5% from the same quarter last year, raising questions about cost pressures even as top-line numbers surprised to the upside.
Revenue Beat Cannot Hide a Widening Loss
HIT's Q2 sales of $8.057 million cleared Wall Street's bar of $7.547 million. That sounds like good news. But the company still lost $0.04 per share — double the expected $0.03 loss, per ScanX Trade. The gap between a solid revenue beat and a worsening loss points to real cost pressure eating into margins.
The 13.5% year-over-year revenue decline adds more context. HIT is bringing in more partners but less money than it did a year ago. That combination — growing distribution, shrinking revenue — suggests pricing or mix shifts may be weighing on results, according to TipRanks.
Distribution Network Grows Even as Revenue Shrinks
One bright spot: HIT grew its distribution partner count by 19.9% year over year, reaching 933 partners as of Q2, according to TipRanks. More partners on the network could mean more revenue down the road. But that growth hasn't translated into dollars yet.
The company appears to be investing in its network now and betting on a payoff later. That strategy explains why management is holding its $45 million to $50 million annual guidance even with soft quarterly numbers. The full-year target requires a significant step-up in the second half of 2026.
Full-Year Guidance Held Steady at $45M–$50M
HIT confirmed its FY2026 sales guidance range of $45 million to $50 million, according to ScanX Trade. The analyst consensus of $46.813 million lands right inside that band. Holding the range steady signals that management believes the business can accelerate — even after a slow Q2.
Stock Titan noted the reaffirmation comes "amid increasing margin pressure." That phrase matters. It tells investors the company knows costs are a problem but still expects revenue to grow enough to hit its targets. It's a cautious but not pessimistic message.
Investor Presentation Filed as Company Courts Wall Street
On August 13, 2026, HIT filed a Form 8-K with an investor presentation attached as Exhibit 99.1. The filing includes forward-looking statements protected under the Private Securities Litigation Reform Act of 1995, according to Stock Titan. The presentation is meant for conferences and investor meetings.
The 8-K material is "furnished" rather than "filed" — a legal distinction that limits liability and keeps it out of other regulatory filings. The move shows HIT is actively talking to investors and trying to keep the market informed as it navigates a choppy first half of the year.
Sentiment
Mostly NegativePublishers
10
Articles
8
Reach
18
